Switch from etanercept to efalizumab in a psoriatic patient with HCV infection: A case report

Dermatologic Therapy

Volumn 22, Issue 4, 2009, Pages 386-390

  Prignano, F ^a   Zanieri, F ^a   Milani, S ^a   Lotti, T ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Efalizumab; Hepatitis C; Psoriasis

Indexed keywords

EFALIZUMAB; ETANERCEPT; VIRUS RNA;

ADULT; ARTICLE; CASE REPORT; COMORBIDITY; DRUG CHOICE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HEPATITIS C; HUMAN; MALE; PSORIASIS VULGARIS; REMISSION; VIRUS LOAD;

ADULT; ANTIBODIES, MONOCLONAL; HEPATITIS C, CHRONIC; HUMANS; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTORS; MALE; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; SEVERITY OF ILLNESS INDEX; VIRAL LOAD;

EID: 67650708702     PISSN: 13960296     EISSN: 15298019     Source Type: Journal    
DOI: 10.1111/j.1529-8019.2009.01251.x     Document Type: Article

References (16)

1. Christophers E. Psoriasis-epidemiology and clinical spectrum. Clin Exp Dermatol 2001 : 26 : 314 320.
2. Finlay AY, Coles EC. The effect of severe psoriasis on the quality of life of 369 patients. Brit J Dermatol 1995 : 132 : 236 244.
3. Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001 : 137 : 280 284. (Pubitemid 32240779)
4. Gupta MA, Gupta AK, Kirby S, et al. Pruritus in psoriasis: a prospective study of some psychiatric and dermatologic correlates. Arch Dermatol 1998 : 124 : 1052 1057.
5. Yosipovitch G, Goon A, Wee J, Chan YH, Goh CL. The prevalence and clinical characteristics of pruritus among patients with extensive psoriasis. Brit J Dermatol 2000 : 143 : 969 973. (Pubitemid 30848089)
6. Gupta MA, Gupta AK, Kirby S, et al. The Psoriasis Life Stress Inventory: a preliminary index of psoriasis-related stress. Acta Derm-Venerol 1995 : 75 : 240 243.
7. Dustin ML, Springer TA. Lymphocyte function-associated antigen-1 (LFA-1) interaction with intercellular adhesion molecule-1 (ICAM-1) is one of at least three mechanisms for lymphocyte adhesion to cultured endothelial cells. J Cell Biol 1998 : 107 : 321 331.
8. Krueger J, Gottlieb A, Miller B, Dedrick R, Garovoy M, Walicke P. Anti-CD11a treatment of psoriasis concurrently increases circulating T-cells and decreases plaque T-cells, consistent with inhibition of cutaneous T-cell trafficking. J Invest Dermatol 2000 : 115 : 333.
9. Lebwohl M, Tyring SK, Hamilton TK, et al., for the Efalizumab Study Group. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 2003 : 349 : 2004 2013.
10. Gordon KB, Papp KA, Hamilton TK, et al. Efalizumab for patients with moderate to severe plaque psoriasis. A randomized controlled trial Reprinted) JAMA 2003 : 290 (23 3073 3080. (Pubitemid 37548113)
11. Menter A, Gordon KB, Carey W, et al. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis Reprinted) Arch Dermatol 2005 : 141 : 31 38. (Pubitemid 40144437)
12. Winterfield LS, Menter A, Gordon K, Gottlieb A. Psoriasis treatment: current and emerging directed therapies. Ann Rheum Dis 2005 : 64 (Suppl. II ii87 ii90.
13. Leonardi CL, Powers JL, Matherson RT et al. Etanercept Psoriasis Study Group. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003 : 349 : 2014 2022.
14. Buggiani G, Lotti T. La rivoluzione terapeutica nella psoriasi: i farmaci biologici. In: Lotti T, ed. LA MEDICINA. Grandi Temi. Dermatologia clinica, 1st ed. Torino, Italy : UTET, 2006 : 451 459.
15. Thaci D, Paetzold S, Kaufmann R, Boehncke W-H. Treatment of psoriasis with alefacept in patients with hepatitis C infection: a report of two cases. Brit J Dermatol 2005 : 152 : 1048 1050. (Pubitemid 40704952)
16. Gottlieb A, Hamilton T, Caro I, Known P, Compton P, Leonardi C. Long-term continuos efalizumab therapy in patients with moderate to severe chronic plaque psoriasis: update results from an ongoing trial. J Am Acad Dermatol 2006 : 54 : S154 63.